Pressman Inc., an independent pharmacy, has filed a class action lawsuit accusing several major pharmaceutical benefit managers (PBMs) of engaging in an unlawful price-fixing scheme.
The complaint, filed on January 7, 2025, in the United States District Court for the Eastern District of New York, targets GoodRx, Inc., GoodRx Holdings, Inc., CVS Caremark Corporation, Express Scripts Holding Company, Medimpact Healthcare Systems, Inc., and Navitus Health Solutions LLC.
The lawsuit claims that these PBMs, which control approximately 95% of the market for processing reimbursement claims for generic prescription medications in the United States, have conspired to fix prices through the Integrated Savings Program (ISP).
Pressman Pharmacy alleges that the program involves sharing competitively sensitive information with GoodRx and using its pricing algorithm to set reimbursement rates. This is said to eliminate competition among PBMs, forcing independent pharmacies to accept lower reimbursement rates.
In a July 2023 statement, GoodRx Interim CEO Scott Wagner revealed that patients could use both their pharmacy benefits and GoodRx discounts simultaneously.
Pressman Pharmacy argues that this arrangement undermines competition between GoodRx and PBMs while benefiting the defendants at the expense of independent pharmacies. The lawsuit contends that without the ISP scheme, PBMs would be required to compete by offering better rebates and reimbursement rates.
Pressman Pharmacy is seeking various forms of relief, including actual damages, restitution, treble damages under antitrust laws like Section 1 of the Sherman Antitrust Act, declaratory relief to nullify agreements within ISP programs, injunctive relief to prevent further profiteering, pre- and post-judgment interest, and reasonable costs, including attorney fees.
Pressman Inc. is represented by attorneys Michael R. Reese and Carlos F. Ramirez from Reese LLP, based in New York City. The case is assigned Case No. 25-cv-115.